Aptose Biosciences Inc. (APTOF): Completion of Acquisition or Disposition of Assets
Aptose Biosciences Inc. (APTOF) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K false 0000882361 0000882361 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30,
How this was made
The 30-second read
Why it matters
APTOF shareholders other than Hanmi affiliates received C$2.41 per share at the effective time; the company is now a wholly owned subsidiary and is expected to be delisted from the TSX around July 3, 2026.
Market read
This is a primary-source confirmation of deal close and cash consideration, which is actionable for holders and deal-arb traders managing convergence and delisting/liquidity risk.
What to watch
Watch for any remaining post-close administrative steps (e.g., Form 15 timing, cash payment/withholding mechanics) that can extend volatility even after deal completion.
Background
The filing is an SEC 8-K (Item 2.01/5.01/8.01) confirming completion of an Arrangement Agreement between Aptose Biosciences, Hanmi Pharmaceuticals, and a Hanmi subsidiary.
Ticker impact
Aptose Biosciences completed its Hanmi acquisition, with each remaining share converted to C$2.41 cash and TSX delisting expected July 3, 2026.
Near-term trading likely compresses toward the cash consideration with elevated liquidity risk into the TSX delisting date.
The 8-K confirms completion, cash conversion per share, and expected TSX delisting; however, the article does not state the current market price or any post-close settlement details.
Market effects
Limited read-across for biotech M&A broadly; this is a single-company corporate action rather than a sector catalyst.
Canadian listing liquidity may thin as TSX delisting approaches, potentially impacting local biotech trading flows.
Low—primarily affects APTOF holders and deal arbitrage positioning rather than global biotech fundamentals.
Counterpoint
If APTOF trades at a meaningful discount/premium to the stated C$2.41, convergence may be slower due to settlement mechanics, FX effects, or residual procedural steps not detailed here.
Key entities
- public_companyAptose Biosciences Inc.
Subject of the 8-K; completed the Hanmi arrangement and will be delisted from the TSX.
- acquirerHanmi Pharmaceuticals Co. Ltd.
Acquired remaining Aptose shares via the arrangement; now controls the company through its wholly owned purchaser.
- acquirer_subsidiaryHS North America Ltd.
Wholly owned Hanmi subsidiary that purchased the remaining Aptose common shares.
